The study was aimed at investigating the repercussions of deficiency in thyroid function with and without thyroid hormone (TH) replacement on the neurochemical entities which underly serotonin (5-HT) neutrotransmission, namely 5-HT1A, 5-HT2A receptors, 5-HT transporter and tryptophan hydroxylase (TPH) in the mature brain. Surgically thyroidectomized male Wistar rats received: (1) an iodine-free diet to produce severe hypothyroidism; (2) hormonal replacement with 15 µg/kg/day of thyroxine (T4) for 21 days to normalize serum TH levels, or (3) hormonal replacement with 200 µg/kg/day of T4 for 14 days to produce an excess of circulating THs. Sham-operated rats were used as controls. Neither hypothyroidism nor an excess in serum TH levels affected 3H-8-OH-DPAT binding to 5-HT1A receptors, 3H-citalopram binding to 5-HT transporter and TPH activity in various brain structures indicating that, in the mature brain, the presynaptic entities of 5-HT neurotransmission are resistant to large variations in TH levels. By contrast, hypothyroid rats had a significant decrease in Bmax of 3H-ketanserin binding to cortical 5-HT2A receptors compared to controls. Cortical 3H-ketanserin binding in thyroidectomized rats was normalized after replacement with low-dose T4. Excess serum TH levels in thyroidectomized rats did not produce any changes in cortical 5-HT2A receptors when compared to thyroidectomized rats with normalized TH levels. The present data suggest that the decrease in cortical 5-HT2A receptors is the main neurochemical event underlying the impairing effect of hypothyroidism on 5-HT neurotransmission.

Keywords:
Serotonin receptors, Serotonin agonists, Thyroid hormones, Tryptophan hydroxylase
1.
Cleare AJ, McGregor A, O’Keane V: Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol 1995;43:713–719.
2.
Cleare AJ, McGregor A, Chambers SM, Dawling S, O’Keane V: Thyroxine replacement increases central 5-hydroxytryptamine activity and reduces depressive symptoms in hypothyroidism. Neuroendocrinology 1996;64:65–69.
3.
Ramalho MJ, Reis LC, Antunes-Rodrigues J, De-Castro-e-Silva E: Thyroidectomy blocks stress-induced prolactin rise in rats: Role of the central serotonergic system. Horm Metab Res 1992;24:462–465.
4.
Joffe RT, Levitt AJ: The thyroid and depression; in Joffe RT, Levitt AJ (eds): The Thyroid Axis and Psychiatric Illness. Washington, American Psychiatric Press, 1993, pp 195–253.
5.
Kirkegaard C, Faber J: The role of thyroid hormones in depression. Eur J Endocrinol 1998;138:1–9.
6.
Musselman DL, Nemeroff CB: Depression and endocrine disorders: Focus on the thyroid and adrenal system. Br J Pharmacol 1996;168(suppl 30):123–128.
7.
Whybrow PC, Prange AJ Jr: A hypothesis of thyroid-catecholamine-receptor interaction. Arch Gen Psychiat 1981;38:106–113.
8.
Hamon M, Bourgoin S, Artaud F, El Mestikawy S: The role of tryptophan uptake and tryptophan hydroxylase in the regulation of serotonin synthesis in the central nervous system. J Physiol (Paris) 1981;77:269–280.
9.
Hjorth S, Sharp T: Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci 1991;48:1779–1786.
10.
Barker EL, Blakey RD: Norepinephrine and serotonin transporters. Molecular targets of antidepressant drugs; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 321–333.
11.
Gerhard CC, van Heerikhuizen H: Functional characteristics of heterologously expressed 5-HT receptors. Eur J Pharmacol 1997;334:1–23.
12.
Zifa E, Fillion G: 5-Hydroxytryptamine receptors. Pharmacol Rev 1992;44:401–458.
13.
Mason GA, Bondy SC, Nemeroff CB, Walker CH, Prange AJ Jr: The effects of thyroid state on beta-adrenergic and serotonergic receptors in rat brain. Psychoneuroendocrinology 1987;12:261–270.
14.
Tejani-Butt SM, Yang J, Kaviani A: Time course of altered thyroid states on 5-HT1A receptors and 5-HT uptake sites in rat brain: An autoradiographic analysis. Neuroendocrinology 1993;57:1011–1018.
15.
Dratman MB: Cerebral versus peripheral regulation and utilization of thyroid hormones; in Joffe RT, Levitt AJ (eds): The Thyroid Axis and Psychiatric Illness. Washington, American Psychiatric Press, 1993, pp 3–94.
16.
Kulikov AV, Castanon N, Mormède P, Chaouloff F: Cerebral tryptophan hydroxylase activity, and 5-HT1A receptor, 5-HT2A receptor, and 5-HT transporter binding in grouped and isolated Roman RHA and RLA rats: Relationships with behaviour in two models of anxiety. Psychopharmacology 1995;121:385–395.
17.
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein-dye binding. Anal Biochem 1976;72:248–254.
18.
Munson PJ, Rodbard D: LIGAND: A versatile computerized approach for the characterization of ligand binding systems. Anal Biochem 1980;107:220–239.
19.
D’Amato RJ, Largent BL, Snowman AM, Snyder SH: Selective labeling of serotonin uptake sites in rat brain by [3H] citalopram contrasted to labeling of multiple sites by [3H] imipramine. J Pharmacol Exp Ther 1987;242:364–371.
20.
Peroutka SJ: Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B and 5-HT1C binding sites in rat frontal cortex. J Neurochem 1986;47:529–540.
21.
Vergé D, Daval G, Marcinkiewitcz M, Patey A, Gozlan H, El Mestikawy S, Hamon M: Quantitative autoradiography of multiple 5-HT1 receptors subtypes in the brain of control and 5,7-DHT treated rats. J Neurosci 1986;6:3474–3482.
22.
Burnet PWJ, Michelson D, Smith MA, Gold PW, Sternberg EM: The effect of chronic imipramine administration on the density of 5-HT1A and 5-HT2 receptors and the abundancies of 5-HT receptor and transporter mRNA in the cortex, hippocampus and dorsal raphe of three strains of rat. Brain Res 1994;638:311–324.
23.
Miquel MC, Doucet E, Boni C, El Mestikawy S, Mathiessen L, Daval G, Vergé D, Hamon M: Central serotonin 1A receptors: Distributions of endogenous mRNA, receptor protein and binding sites by in situ hybridization histochemistry, radioimmunohistochemistry and autoradiographic mapping in the rat brain. Neurochem Int 1991;19:453–465.
24.
Leysen JE, Niemegeers JM, Van Nueten JM, Laduron PM: [3H]Ketanserin (R41 468) a selective ligand for serotonin2 receptor binding sites. Mol Pharmacol 1982;21:301–314.
25.
Hulihan-Giblin BA, Park YD, Aulakh CS, Goldman D: Regional analysis of 5-HT1A and 5-HT2 receptors in the Fawn-Hooded rat. Neuropharmacology 1992;31:1095–1099.
26.
Chaouloff F, Kulikov A, Mormède P: Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical 5-HT2A receptors. Eur J Pharmacol 1997;334:25–29.
27.
Eison AS, Mullins UL: Regulation of central 5-HT2A receptors: A review of in vivo studies. Behav Brain Res 1996;73:177–181.
28.
Leysen JE, Janssen PFM, Neimegeers CJE: Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment. Eur J Pharmacol 1989;163:145–149.
29.
Lafaille F, Welner SA, Suranyi-Cadotte BE: Regulation of serotonin type 2 (5-HT2) and adrenergic receptors in rat cerebral cortex following novel classical antidepressant treatment. J Psychiatr Neurosci 1991;16:209–214.
30.
Willins DL, Deutch AY, Roth BL: Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 1997;27:79–82.
31.
Ruize-Marcos A, Sanchez-Toscano F, Escobar del Rey F, Morreale de Escobar G: Reversible morphological alterations of cortical neurons in juvenile and adult hypothyroidism in the rat. Brain Res 1980;185:91–102.
32.
Gozlan H, Daval G, Vergé D, Stampinato U, Fattaccini CM, Gallissot MC, El Mestikawy S: Aging associated changes in serotonergic and dopaminergic pre- and postsynaptic neurochemical markers in rat brain. Neurobiol Aging 1990;11:437–449.
33.
Mason GA, Walker CH, Prange AJ Jr: L-Triiodothyronine: Is this peripheral hormone a central neurotransmitter? Neuropsychopharmacology 1993;8:253–258.
34.
Maes M, Meltzer HY: The serotonin hypothesis of major depression; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 933–944.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.